CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells

被引：1
|
作者：
Lee, Chansu [1 ]
Ahn, Kwang-Sung [2 ]
Jung, Woo June [1 ]
Koh, Youngil [2 ]
Kim, Hyo Jung [3 ]
Lee, Hyun Jung [4 ]
Yoon, Hwi-Joong [5 ]
Yoon, Sung-Soo [6 ]
机构：
[1] Seoul Natl Univ, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[3] Hallym Univ, Coll Med, Med Ctr, Seoul, South Korea
[4] Dongguk Univ, Ilsan Med Ctr, Seoul, South Korea
[5] Kyung Hee Univ, Sch Med, Med Ctr, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1695
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1695
引用
收藏
页数：1
相关论文
共 50 条
  • [1] THE NOVEL PAN-HDAC INHIBITOR, CKD-581 ENHANCES THE ANTI-MYELOMA EFFECTS OF BORTEZOMIB
    Lee, C.
    Beom, S.
    Ahn, K.
    Jung, W.
    Koh, Y.
    Kim, J.
    Lee, H.
    Kwon, J.
    Kim, H.
    Yoon, H.
    Kim, I.
    Kim, M.
    Kim, B.
    Yoon, S.
    HAEMATOLOGICA, 2013, 98 : 591 - 591
  • [2] Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy
    Hyungwoo Cho
    Dok Hyun Yoon
    Kyu-pyo Kim
    Kyun-Seop Bae
    Won Seog Kim
    Hyeon-Seok Eom
    Jin Seok Kim
    Jung Yong Hong
    Seok Jin Kim
    Hyewon Lee
    Soo-Jeong Kim
    Cheolwon Suh
    Investigational New Drugs, 2018, 36 : 877 - 885
  • [3] Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy
    Cho, Hyungwoo
    Yoon, Dok Hyun
    Kim, Kyu-pyo
    Bae, Kyun-Seop
    Kim, Won Seog
    Eom, Hyeon-Seok
    Kim, Jin Seok
    Hong, Jung Yong
    Kim, Seok Jin
    Lee, Hyewon
    Kim, Soo-Jeong
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 877 - 885
  • [4] Activity of CKD-581, Histone Deacetylase Inhibitor, in Cutaneous T-cell Lymphoma Models
    Kim, M. J.
    Lee, C. S.
    Lee, D. H.
    Yang, H. M.
    Lim, I. T.
    Bae, D. I.
    Choe, Y. J.
    Kim, D. H.
    Kim, S. K.
    Lee, S. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S642 - S642
  • [5] Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells
    Qiao, Zhixin
    Ren, Suping
    Li, Weijing
    Wang, Xuanlin
    He, Min
    Guo, Yingjie
    Sun, Liwei
    He, Yuezhong
    Ge, Yubin
    Yu, Qun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 434 (01) : 95 - 101
  • [6] The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in human multiple myeloma cells.
    Pei, XY
    Dai, Y
    Grant, S
    BLOOD, 2003, 102 (11) : 685A - 685A
  • [7] Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
    He, Yanjuan
    Jiang, Duanfeng
    Zhang, Kaixuan
    Zhu, Yinghong
    Zhang, Jingyu
    Wu, Xuan
    Xia, Jiliang
    Zhu, Yan
    Zou, Lang
    Hu, Jian
    Cui, Yajuan
    Zhou, Wen
    Chen, Fangping
    JOURNAL OF CANCER, 2021, 12 (20): : 6198 - 6208
  • [8] Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma
    Kim, Soo Jin
    Kim, U. Ji
    Yoo, Hae Yong
    Choi, Yong June
    Kang, Keon Wook
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 12
  • [9] CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
    Young Chang
    Yun Bin Lee
    Eun Ju Cho
    Jeong-Hoon Lee
    Su Jong Yu
    Yoon Jun Kim
    Jung-Hwan Yoon
    BMC Cancer, 20
  • [10] CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
    Chang, Young
    Lee, Yun Bin
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    BMC CANCER, 2020, 20 (01)
12345